News
- Author:
- Roxanne Nelson
Publish date: January 4, 2018
Mortality risk was highest in patients who had progressive or refractory disease before a second transplant, or who relapsed within 6 months of a f...
News
- Author:
- Roxanne Nelson
Publish date: January 2, 2018
SAN ANTONIO – Updated analysis fails to confirm that ‘no-tumor on ink’ is optimal.
News
- Author:
- Roxanne Nelson
Publish date: January 2, 2018
SAN ANTONIO – The combo improved outcomes in those who had not received prior endocrine therapy and who were positive for androgen receptor signali...
News
- Author:
- Roxanne Nelson
Publish date: December 27, 2017
SAN ANTONIO – Results from CALGB 40601 conflict with those from two larger trials that failed to find a benefit for dual HER2 blockade in treating ...
News
- Author:
- Roxanne Nelson
Publish date: December 26, 2017
SAN ANTONIO – Long-term follow-up confirms findings at 5 years, that DFS was similar for cohorts randomized to AD or no AD.
News
- Author:
- Roxanne Nelson
Publish date: December 26, 2017
In the phase 3 NeoALTTO trial, the amplification of ERBB2 was shown to be predictive of pCR; its expression was more predictive of pCR.
News
- Author:
- Roxanne Nelson
Publish date: December 19, 2017
Zika RNA can persist in blood components for about up to 3 months.
News
- Author:
- Roxanne Nelson
Publish date: December 18, 2017
SAN ANTONIO – A significant rate of arm swelling and decreased range of motion was seen in young breast cancer patients 1 year after surgery.
News
- Author:
- Roxanne Nelson
Publish date: December 15, 2017
Several studies show incidence of Zika in donor blood correlated to local incidence of disease.
News
- Author:
- Roxanne Nelson
Publish date: December 12, 2017
SAN DIEGO – “The Danish government decided not to discontinue NAT because there were almost no savings.”
News
- Author:
- Roxanne Nelson
Publish date: December 12, 2017
SAN ANTONIO – Treatment with CDK4/6 inhibitors appears to have the same efficacy in older breast cancer patients, as compared with younger ones.
News
- Author:
- Roxanne Nelson
Publish date: December 8, 2017
SAN ANTONIO – The phase 3 SOLD trial failed to show a 9 week course of trastuzumab as noninferior to the standard 12-month course.
News
- Author:
- Roxanne Nelson
Publish date: December 8, 2017
SAN ANTONIO – Women receiving acupuncture had significantly lower joint pain scores in a randomized phase 3 trial.
News
- Author:
- Roxanne Nelson
Publish date: December 7, 2017
SAN ANTONIO – Overall response rate was 34% with sacituzumab govitecan as a single agent among heavily pretreated patients with metastatic TNBC.
News
- Author:
- Roxanne Nelson
Publish date: December 7, 2017
SAN ANTONIO - In a randomized trial of more than 3,000 patients, the five-year IDFS was 89.6% for those who received trastuzumab, compared with 89....
